Trial Profile
Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for subsequent transduction with a lentiviral vector carrying the FANCA gene and reinfusion into the patient
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2016
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Filgrastim
- Indications Fanconi's anaemia
- Focus Adverse reactions; Therapeutic Use
- 08 Jul 2016 Planned initiation date changed from 15 Jun 2016 to 1 Aug 2016.
- 20 Oct 2015 New trial record